Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19935718
Madeo A, et al. (2010) c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells. Oncogene 29, 978-91 19935718
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer, liver cancer, lung cancer, non-small cell lung cancer, prostate cancer
Relevant cell lines - cell types - tissues:  BT-20 (breast cell), HepG2 (hepatic), LNCaP (prostate cell), LoVo (intestinal), MCF-7 (breast cell), NSCLC (pulmonary), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
4-HT increase
PD98059 4-HT inhibit treatment-induced increase
PD98059 no change compared to control
SP600125 4-HT no effect upon treatment-induced increase
SP600125 no change compared to control
4-HT GPER1 (human) increase GPER siRNA inhibits 4-HT-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer, liver cancer, lung cancer, non-small cell lung cancer, prostate cancer
Relevant cell lines - cell types - tissues:  BT-20 (breast cell), HepG2 (hepatic), LNCaP (prostate cell), LoVo (intestinal), MCF-7 (breast cell), NSCLC (pulmonary), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
4-HT increase
PD98059 4-HT inhibit treatment-induced increase
PD98059 no change compared to control
SP600125 4-HT no effect upon treatment-induced increase
SP600125 no change compared to control
4-HT GPER1 (human) increase GPER siRNA inhibits 4-HT-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer, liver cancer, lung cancer, non-small cell lung cancer, prostate cancer
Relevant cell lines - cell types - tissues:  BT-20 (breast cell), HepG2 (hepatic), LNCaP (prostate cell), LoVo (intestinal), MCF-7 (breast cell), NSCLC (pulmonary), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
4-HT increase
PD98059 4-HT inhibit treatment-induced increase
PD98059 no change compared to control
SP600125 4-HT no effect upon treatment-induced increase
SP600125 no change compared to control
4-HT GPER1 (human) increase GPER siRNA inhibits 4-HT-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer, liver cancer, lung cancer, non-small cell lung cancer, prostate cancer
Relevant cell lines - cell types - tissues:  BT-20 (breast cell), HepG2 (hepatic), LNCaP (prostate cell), LoVo (intestinal), MCF-7 (breast cell), NSCLC (pulmonary), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
4-HT increase
PD98059 4-HT inhibit treatment-induced increase
PD98059 no change compared to control
SP600125 4-HT no effect upon treatment-induced increase
SP600125 no change compared to control
4-HT GPER1 (human) increase GPER siRNA inhibits 4-HT-induced increase

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer, liver cancer, lung cancer, non-small cell lung cancer, prostate cancer
Relevant cell lines - cell types - tissues:  BT-20 (breast cell), HepG2 (hepatic), LNCaP (prostate cell), LoVo (intestinal), MCF-7 (breast cell), NSCLC (pulmonary), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
4-HT no change compared to control LNCaP cells

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer, liver cancer, lung cancer, non-small cell lung cancer, prostate cancer
Relevant cell lines - cell types - tissues:  BT-20 (breast cell), HepG2 (hepatic), LNCaP (prostate cell), LoVo (intestinal), MCF-7 (breast cell), NSCLC (pulmonary), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
4-HT no change compared to control LNCaP cells

S73-p - Jun (human)
Modsite: VGLLkLAsPELERLI SwissProt Entrez-Gene
Orthologous residues
Jun (human): S73‑p, Jun (mouse): S73‑p, Jun (rat): S73‑p, Jun (cow): S73‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer, liver cancer, lung cancer, non-small cell lung cancer, prostate cancer
Relevant cell lines - cell types - tissues:  BT-20 (breast cell), HepG2 (hepatic), LNCaP (prostate cell), LoVo (intestinal), MCF-7 (breast cell), NSCLC (pulmonary), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
4-HT increase
SP600125 4-HT inhibit treatment-induced increase
SP600125 no change compared to control
AG1478 4-HT no effect upon treatment-induced increase
AG1478 no change compared to control
faslodex 4-HT no effect upon treatment-induced increase
faslodex no change compared to control
PD98059 4-HT no effect upon treatment-induced increase
PD98059 no change compared to control
4-HT no change compared to control LNCaP cells

T91-p - Jun (human)
Modsite: SNGHItTtPtPtQFL SwissProt Entrez-Gene
Orthologous residues
Jun (human): T91‑p, Jun (mouse): T91‑p, Jun (rat): T91‑p, Jun (cow): T91‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer, liver cancer, lung cancer, non-small cell lung cancer, prostate cancer
Relevant cell lines - cell types - tissues:  BT-20 (breast cell), HepG2 (hepatic), LNCaP (prostate cell), LoVo (intestinal), MCF-7 (breast cell), NSCLC (pulmonary), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
4-HT increase
SP600125 4-HT inhibit treatment-induced increase
SP600125 no change compared to control
AG1478 4-HT no effect upon treatment-induced increase
AG1478 no change compared to control
faslodex 4-HT no effect upon treatment-induced increase
faslodex no change compared to control
PD98059 4-HT no effect upon treatment-induced increase
PD98059 no change compared to control
4-HT no change compared to control LNCaP cells

T93-p - Jun (human)
Modsite: GHItTtPtPtQFLCP SwissProt Entrez-Gene
Orthologous residues
Jun (human): T93‑p, Jun (mouse): T93‑p, Jun (rat): T93‑p, Jun (cow): T93‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer, liver cancer, lung cancer, non-small cell lung cancer, prostate cancer
Relevant cell lines - cell types - tissues:  BT-20 (breast cell), HepG2 (hepatic), LNCaP (prostate cell), LoVo (intestinal), MCF-7 (breast cell), NSCLC (pulmonary), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
4-HT increase
SP600125 4-HT inhibit treatment-induced increase
SP600125 no change compared to control
AG1478 4-HT no effect upon treatment-induced increase
AG1478 no change compared to control
faslodex 4-HT no effect upon treatment-induced increase
faslodex no change compared to control
PD98059 4-HT no effect upon treatment-induced increase
PD98059 no change compared to control
4-HT no change compared to control LNCaP cells